Detalhe da pesquisa
1.
A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency.
Mol Ther
; 31(12): 3457-3477, 2023 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37805711
2.
Interference chromatography: a novel approach to optimizing chromatographic selectivity and separation performance for virus purification.
BMC Biotechnol
; 20(1): 32, 2020 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32552807
3.
Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer.
Front Microbiol
; 15: 1325558, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38328418
4.
Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer.
J Immunother Cancer
; 10(3)2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35296558
5.
Production and purification of high-titer OrfV for preclinical studies in vaccinology and cancer therapy.
Mol Ther Methods Clin Dev
; 23: 434-447, 2021 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34786436
6.
Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models.
Mol Ther Oncolytics
; 20: 306-324, 2021 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33614913
7.
Tumour vasculature: Friend or foe of oncolytic viruses?
Cytokine Growth Factor Rev
; 56: 69-82, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32893095
8.
Quantifying Antigen-Specific T Cell Responses When Using Antigen-Agnostic Immunotherapies.
Mol Ther Methods Clin Dev
; 13: 154-166, 2019 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30788384
9.
Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer.
Mol Ther Methods Clin Dev
; 9: 181-191, 2018 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29556508